Main Menu

N-acetylmannosamine (ManNAc) is a small uncharged physiological molecule that crosses membranes readily and is the natural precursor of intracellular sialic acid synthesis. NHGRI investigators discovered that ManNAc can be used for therapeutic purposes, including treating certain kidney diseases (e.g., those involving abnormal levels of protein in the urine and/or blood in the urine), resulting primarily or secondarily from hyposialylation (deficiency of sialic acid). Notably, ManNAc can also potentially be used to treat diabetic nephropathy.

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption.

Summary:

The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors.

This cutting-edge vaccine technology revolutionizes the field of filovirus immunization by combining adenovirus and vaccinia virus vectors in a prime-boost approach. Its primary objective is to confer comprehensive immunity against various ebolaviruses and marburgviruses, including the most lethal strains. By doing so, it addresses the limitations often associated with single-vector vaccines, providing a more robust and enduring immune response. Moreover, this approach offers flexibility in vaccination scheduling and ensures heightened safety and efficacy.

Cutting-edge research has led to the development of highly potent monoclonal antibodies (mAbs) targeting the circumsporozoite protein (CSP) in the fight against malaria. These fully human recombinant mAbs, isolated from immunized volunteers, exhibit exceptional blocking capacity, with a potency 100 times greater than existing mouse monoclonal CSP antibodies. This breakthrough paves the way for a novel strategy in malaria prevention, offering hope to millions of individuals worldwide, including travelers, military personnel, diplomats, and those residing in malaria-endemic regions.

This technology includes combinations of currently approved antiretrovirals (ARVs) which could allow for simpler dosing regimens that improve adherence to HIV prevention strategies. Event-Driven PrEP (ED-PrEP) with 2 oral doses of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) taken 2-24 hours before sex, a 3rd dose 24 hours after sex, and a 4th dose 48 hours after sex (2+1+1) is considered as a PrEP option by the World Health Organization for men who have sex with men (MSM). Recommended post-exposure prophylaxis (PEP) regimens require 28 days of daily oral dosing.